Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Exclusion Criteria

• •Presence of any disease or condition that might cause nail abnormalities or may interfere with the evaluation of the study drug
• •Use of any systemic antifungal therapy within 4 weeks prior to the Screening visit or non-responsive to systemic antifungal therapy for onychomycosis
• •Use of any prescription or over-the-counter topical antifungal therapy for the toenails within 4 weeks prior to the Screening visit
• •Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period